Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning

Transfusion

Volumn 44, Issue 11, 2004, Pages 1603-1611

  Canals, Carmen ^a   Muñiz Díaz, Eduardo ^a   Martínez, Clara ^a   Martino, Rodrigo ^a   Moreno, Imma ^a   Ramos, Adelaida ^a   Arilla, Marina ^a   Boto, Neus ^a   Pastoret, Concepción ^a   Remacha, Angel ^a   Sierra, Jorge ^a   Madoz, Pedro ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; BLOOD GROUP A; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; BLOOD GROUP KIDD SYSTEM; BLOOD GROUP O; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORTALITY; OUTCOMES RESEARCH; PATIENT; PERIPHERAL BLOOD STEM CELL; PROSPECTIVE STUDY; SURVIVAL; THROMBOCYTOPENIA; TRANSFUSION;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT VS HOST DISEASE; HEMOLYSIS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET TRANSFUSION; RED-CELL APLASIA, PURE; THROMBOCYTOPENIA; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 7244220238     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.04106.x     Document Type: Article

References (31)

1. Rowley SD. Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs. Bone Marrow Transplant 2001;238:315-21.
2. Bensinger WI, Buckner CD, Thomas ED, et al. ABO-incompatible marrow transplants. Transplantation 1982;33:427-9.
3. Mielcarek M, Leisenring W, Torok-Storb B, et al. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Transplantation 2000;96:1150-6.
4. Goldman J, Liesveld J, Nichols D, et al. ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. Leuk Res 2003;27:489-91.
5. Klumpp TR. Immunohematologic complications of bone marrow transplantation. Bone Marrow Transplant 1991;8:159-70.
6. Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000;40:543-50.
7. Salmon JP, Michaux S, Hermanne JP, et al. Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation. Transfusion 1999;39:824-7.
8. Stussi G, Muntwyler J, Passweg JR, et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:87-93.
9. Gmur JP, Burger J. Schaffner, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 1990;75:290-5.
10. Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001;98:1687-94.
11. Je-Hwan L, Jung-Hee L, Seong-June C, et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 2003;120:702-10.
12. Oziel-Taieb S, Faucher-Barbey C, Chabannon C, et al. Early and fatal immune haemolysis after so-called "minor" ABO-incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant 1997;19:1155-6.
13. Valcarcel D, Martino R, Caballero D, et al. Chimerism analysis following allogeneic peripheral blood stem cell trans-plantation with reduced-intensity conditioning. Bone Marrow Transplant 2003;31:387-92.
14. Badros A, Tricot G, Toor A, et al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002;42:205-9.
15. Worel N, Kalhs P, Keil F, et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 2003;43:1153-61.
16. Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning, results of a prospective multicentre study. Br J Haematol 2001;115:653-9.
17. Przepiorka D, Weisdorf D, Martin P, et al. Consense conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-8.
18. Giralt S, Thall P, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-7.
19. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;15:1620-9.
20. Gratwohl A, Baldomero H, Passweg J, et al. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant 2002;30:813-31.
21. Canals C, Martino M, Sureda A, et al. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol 2003;31:1039-43.
22. Weissinger F, Sandmaier BM, Maloney DG, et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001;98:3584-8.
23. Kanda Y, Tanosaki R, Nakai K, et al. Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor. Br J Haematol 2002;118:128-31.
24. Maciej Zaucha J, Mielcarek M, Takatu A, et al. Engraftment of early erythroid progenitors is not delayed after nonmyeloablative major ABO-incompatible haematopoietic stem cell transplantation. Br J Haematol 2002;119:740-50.
25. Santamaria A, Sureda A, Martino R, et al. Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 1997;20:1105-7.
26. Ustun C, Celebi H, Arat M, et al. Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: a case report. Ther Apher 1999;3:275-7.
27. Benjamin RJ, Connors JM, McGurk S, et al. Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 1998;4:151-6.
28. Rabitsch W, Knobl P, Prinz E, et al. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption. Bone Marrow Transplant 2003;32:1015-9.
29. Yamaguchi M, Sakai K, Murata R, et al. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease. Bone Marrow Transplant 2002;30:539-41.
30. Maschan AA, Skorobogatova EV, Balashov DN, et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant 2002;30:405-7.
31. Mehta J, Powles R, Sirohi B, et al. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant 2002;29:853-9.